FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-028								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

37 Estimated average burden hours per response: 0.5

Name and Address of Reporting Person*     Morich Frank					2. Issuer Name <b>and</b> Ticker or Trading Symbol  Cue Biopharma, Inc. [ CUE ]									k all applic Directo	onship of Reporting Ill applicable) Director		10% Ov	vner	
(Last) (First) (Middle) C/O CUE BIOPHARMA, INC.				3. Date of Earliest Transaction (Month/Day/Year) 01/02/2019								Officer below)	(give title		Other (s below)	specify			
21 ERIE STREET  (Street)  CAMBRIDGE MA 02139				4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi Line) X	, ·							
(City)	(5)	-	(Zip)	Doriva	tive	Soc	uritio	- A C	ouired	Die	nosed (	of or Re	nofic	rially	Owned	<u> </u>			
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/D:  Table II - Derivati				2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa Code ( 8) Code	v Disp	4. Securi Disposes 5) Amount	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)  Amount (A) or (D) P  Sed Of, or Benefic		or l and ice	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
1. Title of Derivative Conversion Date 3A. Deemed Execution Date, T			5. Number of Operivative			6. Options, convertil 6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivativ Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4		Beneficial Ownership (Instr. 4)			
				С	ode	V	(A)	(D)	Date Exercisab		Expiration Date	Title	Amor or Numl of Share	ber					
Stock Option (right to buy)	\$5.16	01/02/2019			A		8,000		01/02/202	0 0	01/02/2026	Common Stock	8,00	00	\$0.00	8,000		D	

**Explanation of Responses:** 

Remarks:

/s/ Frank Morich by Mark Busch, as attorney-in-fact

01/03/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.